The costs of treatment of early and chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.
The aim of cystic fibrosis (CF) care is to improve both the life expectancy and quality of life of patients. However, rising costs and limited resources of health services must be taken into account. There are many different antibiotic strategies for therapy of Pseudomonas aeruginosa infection in CF patients. In this 5-year retrospective study we found that the cost of treatment of initial infection is considerably lower than the cost of treating chronic P. aeruginosa infections. The percentage distribution of costs of antibiotic treatment in relationship to the administration route was considerably different between outpatients and inpatients. We observed an increase in antibiotic costs with the age of the patient and the decrease in FEV(1)values. The implementation of early eradication treatment, in addition to decreasing the prevalence of patients chronically infected by P. aeruginosa, might also bring about a notable decrease in costs.
Braccini
G
G
Department of Pediatrics, University of Florence, Italy.
Festini
F
F
Boni
V
V
Neri
A S
AS
Galici
V
V
Campana
S
S
Zavataro
L
L
Trevisan
F
F
Braggion
C
C
Taccetti
G
G
D000328:Adult; D000900:Anti-Bacterial Agents / Q000191:economics* / Q000627:therapeutic use; D002442:Ceftazidime / Q000191:economics / Q000627:therapeutic use; D002675:Child, Preschool; D002908:Chronic Disease; D002939:Ciprofloxacin / Q000191:economics / Q000627:therapeutic use; D002969:Clavulanic Acids / Q000191:economics / Q000627:therapeutic use; D003091:Colistin / Q000191:economics / Q000627:therapeutic use; D017281:Cost of Illness; D003550:Cystic Fibrosis / Q000150:complications / Q000188:drug therapy* / Q000191:economics*; D006801:Humans; D000077731:Meropenem; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000191:economics* / Q000209:etiology; D011550:Pseudomonas aeruginosa; D012189:Retrospective Studies; D013845:Thienamycins / Q000191:economics / Q000627:therapeutic use; D013982:Ticarcillin / Q000191:economics / Q000627:therapeutic use; D014031:Tobramycin / Q000191:economics / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D002969:Clavulanic Acids; D013845:Thienamycins; D002939:Ciprofloxacin; C043215:ticarcillin-clavulanic acid; D002442:Ceftazidime; D013982:Ticarcillin; D000077731:Meropenem; D014031:Tobramycin; D003091:Colistin